Cedars-Sinai Discovery May Aid Doctors in Diagnosing At-risk Patients Before Symptoms Appear
A team led by a Cedars-Sinai physician-scientist has discovered a biomarker—a protein found in the blood—for the most common type of heart failure, a new study published today in JAMA Cardiology shows.
Heart failure with preserved ejection fraction (HFpEF) affects more than 6.5 million Americans each year. And now, thanks to the discovery of the first-ever biomarker for HFpEF, a simple blood test can reveal whether a patient’s heart is not making enough of an important protein. If the protein levels are decreased, the biomarker signal increases and physicians will be able to diagnose heart failure sooner, prescribe corrective medicines and prevent further disease progression.
“By the time heart failure symptoms develop, the critical window for corrective therapy has typically closed,” said Robin Shaw, MD, PhD, the Wasserman Endowed Chair in Cardiology and professor of Medicine at the Smidt Heart Institute at Cedars-Sinai and principal investigator on the study. “Our discovery allows us to not only diagnose the disease sooner, but also to treat patients before that critical period of early intervention for lifesaving care has closed.”
Heart failure with preserved ejection fraction is a condition where the heart can contract, but has problems relaxing—limiting the heart’s ability to fill with blood between each beat—and therefore lowers the amount of blood moving forward with each contraction. Prior to the discovery of the biomarker, clinicians had to wait for patients to have symptoms to make a diagnosis of HFpEF and had to use an echocardiogram that measured how well the heart relaxed. There was no method to gauge the health of the heart muscle before symptoms developed or determine the severity of disease once symptoms were present.
The biomarker—named cBIN1 Score, or CS for short—allows doctors to measure muscle deterioration and measure a protein that regulates the heart’s ability to both contract and relax. As the protein decreases, CS increases, serving as an indication of onset heart failure. The CS biomarker can be measured using a simple blood draw.
This discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician. This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.
Eduardo Marbán, MD, PhD, director, Smidt Heart Institute
The CS biomarker is designed to be used in an outpatient clinic setting. For patients with known HFpEF, doctors can draw a CS level and use it to both guide current care, including medication adjustments, and predict the chances of a patient being admitted to the hospital in the next 12 months.
“More broadly, this discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician,” said Eduardo Marbán, MD, PhD, director of the Smidt Heart Institute. “This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.”
Symptoms of heart failure typically appear as fatigue, fluid weight gain, leg swelling and shortness of breath. Heart failure with preserved ejection fraction is typically diagnosed in elderly people or those living with high blood pressure, diabetes, elevated cholesterol, hypertension, obesity, obstructive sleep apnea, anemia, iron deficiency or diabetes. Its prevalence is projected to rise drastically over the coming decades. Previous studies have shown that women represent the majority of patients diagnosed with the disease.
As next steps, Cedars-Sinai researchers plan on identifying specialty populations in which the CS biomarker could be useful, including sex-based differences, those who have undergone a heart transplant or valve replacement, as well as individuals with no known heart disease or risk factors.
The Latest on: Heart failure
via Google News
The Latest on: Heart failure
- Occlutech’s Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation for Heart Failure (HF)on January 19, 2021 at 10:05 pm
PRNewswire/ -- Occlutech, a privately-held company, announced today that the U.S Food and Drug Administration (FDA) has granted the Company a Breakthrough Device designation for its first-in-class, ...
- Fried food a big factor in heart disease, strokeon January 19, 2021 at 10:05 pm
Eating fried food is tied to an increased risk of heart disease and stroke, a new study suggests. The risk rises with each additional 4-ounce serving per week, a research team in China found. For the ...
- Even small portion of fried foods can increase risk of heart disease, study sayson January 19, 2021 at 3:41 pm
There’s more evidence that eating fried foods may increase your risk for major heart disease and stroke. An analysis published Monday in the journal Heart shows each additional weekly serving of 114 ...
- Catheter Stimulates Lymphatic Drainage for Heart Failure Treatment: Interview with Eamon Brady, CEO of WhiteSwellon January 19, 2021 at 3:39 pm
WhiteSwell, a medtech company based in Galway, Ireland, has developed a catheter system to treat acute decompensated heart failure (ADHF). ADHF is often ...
- Just a half-cup of fried food a week increases your risk of heart disease, study findson January 19, 2021 at 12:49 pm
One medium serving of McDonald's French fries per week was associated with increased risks of heart attack, stroke, heart disease, and heart failure.
- Pastor’s fatal heart attack at 32 points to chronic disease crisis among young black maleson January 19, 2021 at 10:43 am
A 32-year-old Texas pastor\'s fatal heart attack may be a casualty of an “emerging chronic disease crisis” among young black American males, recent but limited research suggests.
- Eating more fried food can increase the risk for heart disease and strokeon January 19, 2021 at 8:56 am
Diet has been closely linked with heart disease risk, and many recent studies have touted the benefits of consumers opting for more plant-based options as ...
- Study: Death rate of heart failure patients nearly doubled with onset of COVID-19on January 19, 2021 at 7:36 am
It’s well known that patients suffering from a number of conditions are at greater risk of death from a COVID-19 infection—and a new study finds a link between the onset of COVD-19 protocols and acute ...
- Hypothetical case suggests genetic testing has significant limitations for predicting disease in a healthy patienton January 19, 2021 at 12:35 am
Despite its utility as a diagnostic tool in patients with specific risk factors for genetic disease, genetic testing still has significant limitations for predicting disease in a healthy patient.
via Bing News